Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer

Fineline Cube May 11, 2026
Company Drug

CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion

Fineline Cube May 11, 2026
Company

AstraZeneca’s Gracell Biotechnologies to Expand Cell Therapy Manufacturing in China

Fineline Cube Jun 20, 2024

Gracell Biotechnologies, a China-based cell therapy specialist owned by AstraZeneca (AZ; NASDAQ: AZN), is reportedly...

Company Drug

NMPA Releases 81st Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jun 19, 2024

The National Medical Products Administration (NMPA) has released the 81st batch of reference drugs for...

Company Deals

Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion

Fineline Cube Jun 19, 2024

Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has...

Company Deals

3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion

Fineline Cube Jun 19, 2024

3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term...

Company Medical Device

Hybribio Ltd Secures NMPA Approval for α-Thalassemia Genotyping Detection Kit

Fineline Cube Jun 19, 2024

Hybribio Ltd (SHE: 300639), a Guangdong-based provider of nucleic acid molecular diagnostic products, has announced...

Company Drug

Kanghong Pharmaceutical’s Lumitin Approved in Myanmar for Neovascular AMD Treatment

Fineline Cube Jun 19, 2024

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...

Company Drug

Suzhou Zelgen’s Recombinant Human Thyroid Stimulating Hormone Accepted for NMPA Review

Fineline Cube Jun 19, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Deals

Sanofi Partners with Belharra Therapeutics to Tap into Chemoproteomics for Immunology Targets

Fineline Cube Jun 19, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), a major French pharmaceutical company, has formed a collaboration with...

Company Drug

Clover Biopharmaceuticals’ RSV Vaccine Candidate Shows Promising Results in Elderly

Fineline Cube Jun 19, 2024

Clover Biopharmaceuticals Ltd. (HKG: 2197), a biopharmaceutical company based in China, has announced positive preliminary...

Company Deals

Day One Biopharmaceuticals Expands Pipeline with MabCare Therapeutics Licensing Deal

Fineline Cube Jun 19, 2024

Day One Biopharmaceuticals (NASDAQ: DAWN), a California-based biotech company that recently celebrated its first drug...

Company Drug

China Medical System’s Methylthioninium Tablets Get NMPA Green Light for Colonoscopy Use

Fineline Cube Jun 19, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received New Drug...

Company Drug

AstraZeneca’s AKT Inhibitor Truqap Misses Primary Endpoints in Phase III TNBC Trial

Fineline Cube Jun 19, 2024

AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has encountered a setback in the Phase...

Company Drug

MSD’s Capvaxive Vaccine Targets 21 Serotypes of Streptococcus Pneumoniae

Fineline Cube Jun 19, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced...

Company Deals

Roche Secures RNA Exon Editing Tech for Neurological Diseases with Ascidian Deal

Fineline Cube Jun 19, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY), a Swiss pharmaceutical giant, is expanding its footprint in the...

Policy / Regulatory

Gansu Province Introduces Measures for Management of Pharmaceutical Personnel

Fineline Cube Jun 18, 2024

The Gansu Medical Products Administration has issued a set of “Measures for the Management of...

Policy / Regulatory

Guangdong Pharmaceutical Association Expands Off-Label Drug Use Catalogue for 2024

Fineline Cube Jun 18, 2024

The Guangdong Pharmaceutical Association (GDPA) has released the Off-label Drug Use Catalogue for the year...

Company Drug

Envonalkib, Chia Tai Tianqing’s Next-Gen ALK Inhibitor, Wins NMPA Approval for Untreated ALK+ NSCLC

Fineline Cube Jun 18, 2024

Chia Tai Tianqing’s next-generation ALK inhibitor, envonalkib, has received approval from the National Medical Products...

Company Drug

Ascentage Pharma Presents Positive Clinical Results for Olverembatinib and Lisaftoclax at EHA Meeting

Fineline Cube Jun 18, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has presented the results of...

Company

AstraZeneca Restructures County Oncology Team to Enhance Vertical Alignment

Fineline Cube Jun 18, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading global biopharmaceutical company, is planning to restructure and spin...

Company Drug

Nanjing Sanhome’s Oritinib Wins NMPA Approval for EGFR T790M Positive NSCLC

Fineline Cube Jun 18, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd has received approval from the National Medical Products Administration (NMPA)...

Posts pagination

1 … 340 341 342 … 663

Recent updates

  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer
  • CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion
  • NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards
  • Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
  • European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer

Company Drug

CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion

Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.